Asante Solutions announced that it is ceasing all business operations and will no longer sell or support the Asante Snap Insulin Pump. This means all current Asante Snap Insulin Pump users will soon need to transition to a new insulin pump. Read more
The U.S. Food and Drug Administration (FDA) approved Becton Dickinson Medical’s (BD) application to begin production of its novel FlowSmart insulin infusion set, designed to improve insulin delivery with less pain. The FlowSmart insulin infusion set was developed in collaboration with JDRF and the Helmsley Charitable Trust. Read more
The European Commission has granted Sanofi marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), for the treatment of type 1 and type 2 diabetes mellitus in adults. Toujeo is a next-generation, once-daily basal insulin based on a broadly-used molecule (insulin glargine) with a well-established benefit-risk profile. Read more
The U.S. Food and Drug Administration (FDA) approved Sanofi’s new once daily long acting insulin, Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) for treatment of adults living with type 1 and type 2 diabetes.
Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen which contains 450 units of Toujeo and requires one third of the injection volume to deliver the same number of insulin units as compared to the Lantus SoloSTAR. Read more
Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it will invest in a novel scientific approach, called disease interception, to find ways to intercept type 1 diabetes using new diagnostic and pre-disease intervention strategies. If successful, this approach has the potential to transform the standard of care in type 1 diabetes.
Knowing more about the type of T cell that causes type 1 is definitely good news for future treatments… Read more
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company’s Glyxambi for treatment of adults with type 2 diabetes.
Glyxambi is the first and only diabetes treatment in the U.S. to combine the dual mechanisms of …. Read more
Medtronic, Inc. announced the global launch of the MiniMed 640G System, the next breakthrough toward an artificial pancreas.
The system is the first in the world to both automatically suspend insulin delivery when sensor glucose levels are predicted to approach a low limit, and then resume insulin delivery once sensor glucose levels recover. Read more
The U.S. FDA has granted the Tandem Diabetes Care clearance to market the t:flex Insulin Pump. At 480 units, the insulin reservoir of the t:flex Pump has the largest capacity currently available in the United States. The t:flex Pump is designed for people who require more than 100 units of U-100 insulin per day, such as teenagers with type 1 diabetes and many people with type 2 diabetes… Read more
The American Diabetes Association (ADA) has decided to lower the Body Mass Index (BMI) cut point at which it recommends screening Asian Americans for type 2 diabetes. This change in ADA guidelines is aligned with evidence that many Asian Americans develop the disease at lower BMI levels than the population at large, according to a position statement being published in the January issue of Diabetes Care. Read more